Century Therapeutics (IPSC) Equity Average (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Equity Average data on file, last reported at $211.8 million in Q1 2026.

• Equity Average for Q1 2026 came in at $211.8 million, up 5.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $211.8 million (up 5.45% YoY), and the FY2025 annual result was $160.1 million, down 7.46% from the prior year.
• Equity Average rose to $211.8 million in Q1 2026 per IPSC's latest filing, from $167.6 million in the prior quarter.
• Over five years, Equity Average peaked at $391.5 million in Q1 2022 and troughed at $167.6 million in Q4 2025.
• A 5-year average of $245.8 million and a median of $211.8 million in 2026 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average jumped 495.47% in 2022, then plunged 37.47% in 2024.
• A 5-year view of Equity Average shows it stood at $316.5 million in 2022, then tumbled by 36.17% to $202.0 million in 2023, then fell by 11.62% to $178.5 million in 2024, then slipped by 6.1% to $167.6 million in 2025, then advanced by 26.36% to $211.8 million in 2026.
• Business Quant data shows IPSC's Equity Average at $211.8 million in Q1 2026, $167.6 million in Q4 2025, and $193.1 million in Q3 2025.